Discovering Novel Combinations through In Vitro Neurogenesis
With the BrainCells platform, existing
drugs can be tested in combination to
identify pairings that show favorable neurogenic profiles.
The Platform in Practice
For the first time, there is a rational drug identification and development process for central nervous system disease. BrainCells is using its proprietary neurogenesis platform to profile compounds and targets and compare them to both successful and failed CNS compounds.
A Predictive Tool for Drug Identification and Development.
BrainCells believes that being able to understand how different compounds influence neurogenesis can measurably increase the odds of CNS drug development success. Through the neurogenesis platform and our ability to study the direct biologic effect compounds have on new neuron formation, we will be better able to predict a compound’s clinical performance.
Having already tested more than 1,000 compounds across over 150 mechanisms in its neurogenesis assays, BrainCells has developed an extensive knowledge base expanding our understanding of the neurogenic fingerprint.
BrainCells believes the profiles of marketed drugs to treat classes of CNS indications, such as depression, anxiety, psychoses, cognition, schizophrenia and brain repair, are distinct from one another. BrainCells is using this information to select and repurpose clinical stage compounds with established safety databases, and to discover novel targets and compounds to treat CNS disorders.